Pro 2014-023 (Announcement of 18th Resolution of 8th Jianfeng Group)
Release time:
2020-08-05
Stock Code: 600668 Stock Abbreviation: Jianfeng Group No.: Pro 2014-023
Bond Abbreviation: 13 Jianfeng 01 Bond Code: 122227
Zhejiang Jianfeng Group Co., Ltd.
18th Board of Directors Resolution Announcement
The board of directors and all directors of the company guarantee that the content of this announcement does not contain any False records, misleading statements or major omissions, and bear individual and joint responsibility for the authenticity, accuracy and completeness of its contents .
On August 14, 2014, Zhejiang Jianfeng Group Co., Ltd. issued a notice to convene the 18th meeting of the 8th Board of Directors by fax, e-mail, telephone and personal delivery. On August 25, 2014, the meeting was held as scheduled in the conference room of Jianfeng Building in Jinhua, Zhejiang. The meeting was presided over by Chairman Jiang Xiaomeng. Independent director Liu Jiajian entrusted independent director Zhang Yuyou to attend the meeting and vote due to a business trip. The remaining seven directors attended the meeting in person. The company's supervisors and senior management personnel attended the meeting as nonvoting delegates, which complied with the Company Law and the company's The relevant provisions of the Articles of Association are legal and valid. The meeting passed the following resolution:
1. passed the company's 2014 semi-annual report.
Voting result: 8 votes in favor, 0 votes against and 0 abstentions.
The 2. passed the proposal on the public issuance of corporate bonds (Phase II)
After deliberation and voting, the board of directors passed the proposal.
According to the Securities Regulatory License [2013] No. 595 and the "Proposal on the Issuance of Corporate Bonds" reviewed and approved by the company's first extraordinary general meeting of shareholders in 2013, combined with the company's actual capital needs, it is proposed to publicly issue Zhejiang Jianfeng Group Co., Ltd.'s 2013 corporate bonds (second phase) (the specific bond name is subject to the final confirmation of the relevant regulatory agency), with a total issuance of RMB 0.3 billion, the term of the bonds is 5 years (with the issuer's interest rate increase option and the investor's resale option at the end of the third year) , and all the proceeds are used to supplement working capital and are not given priority placement to the original shareholders. The company's board of directors will handle matters related to the company's current public issuance of corporate bonds in accordance with relevant laws and regulations, the requirements of the above-mentioned approval documents and the authorization of the company's shareholders meeting.
Voting result: 8 votes in favor, 0 votes against, 0 abstentions.
hereby announces
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
August 25, 2014
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page